Smartlens

Smartlens is a clinical-stage medical device company founded in 2015 and headquartered in the United States, dedicated to transforming anterior segment disease management through breakthrough wearable and AI-powered technologies. The company's flagship product, miLens, is the world's smallest electronics-free wearable microfluidic contact lens for diurnal intraocular pressure (IOP) monitoring — the primary risk factor for glaucoma, the leading cause of irreversible blindness worldwide. Currently in U.S. pivotal trials, miLens enables continuous, non-invasive IOP monitoring anywhere and anytime, capturing critical pressure variations missed by traditional quarterly or annual office measurements. The platform is backed by 40+ global patents and an exclusive Stanford University license, with foundational research published in Nature Medicine. Smartlens also develops THERx IQ, an automated micro-dose medication delivery wearable, and miLens IQ+, an AI/ML-powered analytics platform integrating IOP and imaging data for predictive risk stratification. With 96.2% practitioner adoption intent in U.S. trials, the company is advancing toward commercial launch to address the 56% of glaucoma patients in the U.S. who remain undiagnosed.